Role of Monoclonal Antibodies in the Treatment of Asthma

BACKGROUND: Patients with severe refractory asthma represent a small subset of the asthmatic population (between 5% and 10% of all patients) but are the greatest burden to the health care system. New treatment approaches developed to manage some of the phenotypes of severe refractory asthma have included humanized monoclonal antibodies (hMabs). OBJECTIVE: To review the evidence and ascertain whether hMabs provide clinical benefit to patients …